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Tumour cells become addicted to the expression of initiating oncogenes like Ras, such that loss of oncogene expression in established tumours leads to tumour regression 1 . HRas, NRas or KRas are mutated to remain in the active GTP-bound oncogenic state in many cancers 2 . Although Ras activates several proteins to initiate human tumour growth, only PI3K, through activation of protein kinase B (PKB; also known as AKT), must remain activated by oncogenic Ras to maintain this growth 3 . Here we show that blocking phosphorylation of the AKT substrate, endothelial nitric oxide synthase (eNOS or NOS3), inhibits tumour initiation and maintenance. Moreover, eNOS enhances the nitrosylation and activation of endogenous wild-type Ras proteins, which are required throughout tumorigenesis. We suggest that activation of the PI3K-AKT-eNOS-(wild-type) Ras pathway by oncogenic Ras in cancer cells is required to initiate and maintain tumour growth.
The reduction of Ras oncogene dependence to activation of AKT appears to be a consequence of redundant signalling provided by the established tumour microenvironment. Indeed, activation of AKT fosters tumorigenic growth of otherwise non-tumorigenic cells, provided such cells are mixed with tumour cells to establish the tumour microenvironment 3 . We exploited this cell-mixing assay to interrogate the signalling pathway downstream of AKT required for tumour maintenance. Although AKT can phosphorylate several proteins 4 , we focused on BAD, FOXO, IKKa, TSC2 and eNOS, as the consequence of AKT phosphorylation of these proteins is not redundant with the functions of the oncoproteins expressed in cells used in the cellmixing assay of tumour maintenance 5 ( Supplementary Fig. 1 ). Non-tumorigenic PI3K-TtH LacZ cells, derived from normal human kidney cells transformed by oncoproteins T/t-Ags and immortalized by hTERT (hereafter termed TtH cells), and which expressed p110-CAAX (to activate the PI3K-AKT pathway) and LacZ (to demark the cells in the tumour), had Bcl-X L short hairpin RNA (shRNA), eNOS shRNA or, as reported by others [6] [7] [8] , dominant-acting FOXO3a-A3 or TSC2 SA,TA (mutated at AKT phosphorylation sites), or IKKa
K44A
(kinase-inactive) proteins expressed to suppress the effects of AKT on these individual pathways ( Supplementary Fig. 1 ). Knockdown of Bcl-X L and eNOS, ectopic expression and nuclear localization of FOXO3a-A3 (ref. 6 ), ectopic expression of TSC2 SA,TA leading to mTOR repression, as assessed by decreased S6k phosphorylation 7 , and ectopic expression of IKKa K44A leading to repression of NF-kB, as assessed by nuclear exclusion of p65 8 , were validated (Supplementary Fig. 2 ). These five cell lines were mixed with tumorigenic HRas G12V -transformed TtH cells (termed Ras G12V -TtH cells) to establish a tumour microenvironment, injected into mice, and assayed for their contribution to the resultant tumour mass by treating tumours or derived tumour cells with X-gal to stain LacZ 1 cells blue. Positive control vector PI3K-TtH LacZ cells extensively populated tumours, whereas negative control vector TtH LacZ cells contributed little to the tumour mass, as evidenced by the prominent or weak blue staining, respectively. Expression of IKKa K44A had little effect; Bcl-X L shRNA, FOXO3a-A3 and TSC2 SA,TA had a mild effect; however, eNOS shRNA had the greatest effect on reducing the contribution of PI3K-TtH LacZ (blue) cells in tumours (Fig. 1a) . To test if AKT phosphorylation, not just expression of eNOS, is required for tumour maintenance, AKT was validated to phosphorylate S 1177 of eNOS [9] [10] [11] . This was evidenced by a loss of S 1177 phosphorylation of endogenous eNOS upon pharmacological inhibition of AKT signalling with LY294002, or by mutating S 1177 of ectopic eNOS to alanine in PI3K-TtH LacZ cells (Fig. 1b) . PI3K-TtH LacZ cells in which eNOS was knocked down were then engineered to express eNOS R in the wild-type or S 1177 A mutant configuration (Supplementary Fig. 3 ), and assayed for tumour maintenance by the aforementioned cell-mixing assay. Control PI3K-TtH LacZ cells populated tumours, and this contribution was greatly reduced upon knockdown of eNOS, as evidenced by the reduction in blue staining. This loss was rescued by wild-type, but not S 1177 A, mutant eNOS R (Fig. 1c) . Thus, activation of the PI3K-AKT-eNOS pathway promotes tumour maintenance.
eNOS has been detected in tumour cells 12 , and catalyses the synthesis of nitric oxide. This can facilitate S-nitrosylation of the thiol group of cysteines in proteins 13 , such as that of C 118 of HRas, which enhances the dissociation of guanine nucleotides, thereby increasing GTP-bound HRas 14 . Wild-type Ras proteins can be required for activation of the MAPK pathway by oncogenic Ras 15 and membrane targeting of RasGAP, which inhibits wild-type but not oncogenic Ras, reverts oncogenic Ras transformation of NIH3T3 cells 16 . This suggests that wild-type Ras proteins may facilitate oncogenic signalling. Collectively, we speculated that AKT activation of eNOS maintains tumour growth in the absence of oncogenic Ras by activating wildtype Ras through S-nitrosylation of C 118 . To test this, activated AKT in PI3K-TtH was shown to foster HRas nitrosylation through eNOS. Specifically, most HRas nitrosylation was lost by treatment with the PI3K inhibitor wortmannin (Fig. 2a) , by mutating C 118 in HRas to serine (a minor change that exchanges the sulphur atom for oxygen but nevertheless blocks nitrosylation 14 ) (Fig. 2b ), or by knocking down eNOS (Fig. 2c) . Conversly, HRas nitrosylation was elevated upon activation of AKT by p110-CAAX (Fig. 2c) . Reduction of HRas nitrosylation by eNOS shRNA also reduced levels of active GTP-bound HRas (Fig. 2c) . Because TtH cells express HRas and NRas, but not KRas (not shown), and C 118 is conserved among all Ras proteins, we tested and confirmed that activated AKT in PI3K-TtH cells also led to elevated levels of nitrosylated and GTP-bound endogenous NRas, which were reduced upon knockdown of eNOS (Fig. 2c) . Thus, AKT activation of eNOS promotes nitrosylation and activation of wild-type Ras proteins. Then, to assess the biological consequence of S-nitrosylation of wild-type HRas in tumour maintenance, we tested whether replacing endogenous wild-type HRas with the nitrosylation-resistant C 118 S mutant version reduced tumour maintenance. HRas was knocked down by shRNA in PI3K-TtH (Fig. 2d) . Thus, activation of the PI3K-AKT-eNOS pathway promotes tumour maintenance by S-nitrosylation and activation of wild-type Ras.
As oncogenic Ras must activate the PI3K-AKT pathway both to initiate and maintain tumour growth 3 , we tested whether AKTmediated activation of eNOS was also required for the establishment of tumours. A scramble control or eNOS shRNA was introduced into tumorigenic Ras G12V -TtH cells, and knockdown of eNOS complemented by RNAi-resistant eNOS (eNOS R ) in the wild-type or S 1177 A mutant configuration resistant to S 1177 phosphorylation (Supplementary Fig. 5 ). These four cell lines were injected into mice, and tumour growth monitored over time. Scramble control cells rapidly formed tumours, whereas tumour growth was almost abolished upon knockdown of eNOS. This loss of tumour growth was rescued by the wild-type, but not the S 1177 A version, of eNOS R ( Fig. 3a and Supplementary Fig. 6 ), indicating that S 1177 phosphorylation of eNOS is required for tumour initiation and maintenance. These results were validated in a chemical carcinogen-induced spontaneous Ras-driven cancer model. DMBA (7,12-dimethylbenz(a)anthracene) followed by 12-O-tetradecanoylphorbol-13-acetate (TPA) were topically applied to eNOS 1/1 and eNOS 2/2 mice to induce skin papillomas characterized by Ras oncogenic mutations 17 . The result was an (Fig. 3b and Supplementary Fig. 7) . Thus, independent models of cancer demonstrate eNOS is required for tumorigenesis.
To test whether eNOS mediates oncogenic Ras signalling in a cancer associated with the most commonly mutated Ras family member, KRas 2 , the amount of activated (S 1177 phosphorylated) eNOS was first assayed in cancer cell lines and tumour specimens isolated from patients diagnosed with pancreatic cancer. Compared with normal tissue specimens, CFPac-1, MIAPaCa-2 and Capan-1 cells exhibited the highest level of S 1177 phosphorylation of eNOS (Fig. 4a) . Activated KRas and S 1177 -phosphorylated eNOS were also elevated in the tumour specimens compared with matched and unmatched normal tissue controls (Fig. 4b and ref. 18) , with the caveat that biopsies also contained stromal tissue that could have contributed to detected eNOS phosphorylation.
Next, we tested whether eNOS was required for pancreatic tumour growth. Knockdown of eNOS reduced tumour growth by 50-fold in CFPac-1 cells, and tumour size of MIAPaCa-2 cells by 80% (Fig. 4c , and Supplementary Figs 8 and 9) . As a control, knockdown of eNOS in cell lines AsPc-1 and SW1990, which exhibited poor eNOS activation, had no obvious effect on tumour growth (data not shown). Using a more direct assay for tumour maintenance, in vivo doxycycline (dox)-induced shRNA knockdown of eNOS in CFPac-1 and MIAPaCa-2 cells after tumours were established inhibited tumour growth, as evidenced by reduced size and/or gross necrosis of tumours excised at the termination of the experiment (Fig. 4d) . In some mice, this eventually led to tumour regression (data not shown). Thus, eNOS is required both to initiate and maintain tumour growth of these human pancreatic cancer cells.
To test whether eNOS promoted tumour growth through nitrosylation of Ras in pancreatic cancer cells, we determined which Ras family members were inactivated by eNOS shRNA in CFPac-1 and MIAPaCa-2 cells. Not surprisingly, GTP-bound KRas was unchanged on knockdown of eNOS ( Fig. 4c and Supplementary Fig. 9 ), as KRas is mutated to remain active in these two cell lines 19, 20 . Consistent with this, oncogenic KRas harbouring the C 118 S mutation remained tumorigenic ( Supplementary Fig. 10 ), pointing towards wild-type Ras proteins as the target of eNOS signalling. Indeed, GTP-bound endogenous wild-type HRas and NRas were reduced upon shRNA knockdown of eNOS. Moreover, as the wild-type allele of KRas is deleted in MIAPaCa-2 cells 20 , several oncogenic KRas-positive cell lines 20 and tumour tissues 21 , wild-type HRas and NRas, but not KRas, appear to be the targets of eNOS signalling in pancreatic cancer cells (Fig. 4c and Supplementary Fig. 9 ).
To test if activation of HRas or NRas by eNOS is required for pancreatic tumour growth, HRas or NRas were knocked down by shRNA in CFPac-1 and/or MIAPaCa-2 cells and complemented with an HRas or NRas that was engineered to be resistant to RNAi (HRas R , NRas R ) in the wild-type or C 118 S mutant configuration. Resultant cells were then assayed for tumour growth in mice. Positive control, scramble-treated CFPac-1 and/or MIAPaCa-2 cells readily formed tumours in mice, whereas this growth was reduced when endogenous HRas, and to a lesser degree NRas, was knocked down. This loss of tumour growth was rescued by expressing the appropriate wild-type HRas or NRas, but not the C 118 S nitrosylation mutants (Fig. 4e, f and Supplementary Figs 11-13 ). Similar results were found when the cells were assayed for transformed growth in vitro, suggestive of a tumour-cell autonomous defect when wild-type Ras proteins cannot be nitrosylated (Supplementary Fig. 14) . Thus, oncogenic KRasdriven pancreatic cancer tumour growth was mediated by eNOS nitrosylation of endogenous wild-type HRas and NRas (Fig. 4g) .
In summary, we demonstrate that the continual need for PI3K-AKT signalling during initiation and maintenance of oncogenic Ras-driven tumour growth is due, at least in part, to activation of eNOS through phosphorylation of S 1177 . This in turn leads to S-nitrosylation at C 118 and correspondingly activation of the other wild-type Ras family members, perhaps as a means to diversify the Ras signal beyond that of oncogenic Ras (Fig. 4g) . In agreement, the wild-type counterpart of oncogenic Ras is not required for tumorigenesis ( Supplementary Fig. 15 ), and is even deleted in some tumours 21, 22 ; whereas wild-type HRas and NRas are required for oncogenic KRasdriven tumour growth, and appear to have non-redundant activies [23] [24] [25] [26] . Effects of eNOS on tumorigenesis have been largely attributed to its activity in endothelial cells 12 . Our results now suggest a key role for tumour-expressed eNOS in the tumorigenic process. Because eNOS plays multiple roles in tumorigenesis 12 , and delivery of a peptide fragment of the protein cavtratin, which can inhibit eNOS, displays anti-tumour activity 27 , we speculate that inhibition of eNOS, perhaps in combination with inhibition of wild-type Ras protein function or processing 2 , could have therapeutic value in the treatment of oncogenic Ras-driven human cancers such as those of the pancreas.
METHODS SUMMARY
TtH and the pancreatic cancer cell lines were stably infected retroviruses encoding the indicated shRNAs, transgenes or no insert as described 5 , and appropriate expression verified by immunoblot or polymerase chain reaction with reverse transcription (RT-PCR). Detection of GTP-bound or nitrosylated Ras was performed as described in Methods. One or a mixture of two cell lines were injected into the flanks of immunocompromised mice to assay for tumour growth; where indicated, they were excised and assayed for LacZ-positive cells, as described 3 . Induction of shRNA in vivo by dox 3 and DMBA/TPA treatments 28 were performed as described.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
